CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ -- Invaio Sciences,
Inc., a Flagship Pioneering company focused on unlocking the
potential of the planet's interdependent natural systems to solve
pressing agriculture, nutrition and environmental challenges,
announced today the appointment of Peleg
Chevion as President and Chief Commercial Officer.
Chevion, who joined the company in late 2020, will focus on
accelerating the commercial activities of the company.
"Our goal at Invaio is to accelerate the transition in
agriculture from a chemical-based industry to a biological-based
industry that addresses the needs of farmers and society, while
protecting the environment," said Ignacio
Martinez, Co-Founder and CEO, Invaio. "The company is now
transitioning from an R&D-focused organization to a full
commercial enterprise."
Martinez continued, "Peleg has already made a significant impact
at Invaio since he joined the company in late 2020. He brings a
very unique set of experiences, commercial leadership, and an
entrepreneurial mindset perfectly suited for the next phase of the
company."
Prior to joining Invaio, Chevion was President and Chief
Commercial Officer of Blendhub, a global leader in food and
ingredients production. Before Blendhub, Peleg worked with
Lindsey Goldberg, a leading global
private equity firm based in New
York. Chevion also worked for seven years as a senior
executive at Syngenta where he started and then led the Abiotic
Stress Management indication across the spectrum of chemical,
biological, genetics and digital platforms. Prior to Syngenta,
Chevion spent several years leading Business Development at Crucell
before the company was acquired by J&J.
Chevion began his career as an officer in the Israeli Air Force,
and later held diverse roles in the Israeli startup
ecosystem. Chevion graduated from the IDF Computer Academy.
He received an L.L.B from Tel Aviv
University, an MBA from INSEAD and is a licensed attorney in
Israel.
"Since joining Invaio last year, I have been impressed by the
breakthrough platform technologies we are developing, our
integrated solutions approach and the commercial traction of the
company," said Peleg Chevion,
President and Chief Commercial Officer, Invaio. "We are curing
diseases like Greening in Citrus and Xylella in Olives,
significantly reducing the use of chemicals with our precision
delivery systems, and discovering biological products with
consistent performance using proprietary Artificial Intelligence
and Machine Learning technologies"
Chevion continues, "We are laser focused on developing unique
solutions for our partner growers and other stakeholders in three
segments: perennials, row crops and vegetable crops. We see the
opportunity and have a sense of urgency to deliver."
About Invaio Sciences:
Invaio Sciences is a
multi-platform technology company that unlocks the potential of the
planet's interdependent systems to address pressing agricultural,
nutritional, and environmental challenges. Founded by Flagship
Pioneering in 2018, Invaio leverages discoveries from diverse
fields including human therapeutics, agriculture, environmental
science, and advanced manufacturing. The company's deep
understanding of the physiology of insects, plants and trees,
together with its novel integrated solutions approach, promises to
refine agricultural practices and reduce the need for pesticides
globally. Invaio Sciences is dedicated to developing solutions that
are mindful of beneficial insects, bad for pests, and safer for us
all. For more information, please visit www.invaio.com
About Flagship Pioneering:
Flagship Pioneering
conceives, creates, resources, and develops first-in-category life
science platform companies to transform human health and
sustainability. Since its launch in 2000, the firm has, through its
Flagship Labs unit, applied its unique hypothesis-driven innovation
process to originate and foster more than 100 scientific ventures,
resulting in over $80 billion in
aggregate value. To date, Flagship has deployed over $2.3 billion in capital toward the founding and
growth of its pioneering companies alongside more than $19 billion of follow-on investments from other
institutions. The current Flagship ecosystem comprises 41
transformative companies, including Axcella Health (NASDAQ: AXLA),
Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ:
DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics
(NASDAQ: FHTX), Indigo Ag, Inari
Agriculture, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ:
MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology
(NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon
Therapeutics (NASDAQ:SGTX).
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invaio-sciences-strengthens-leadership-team-with-appointment-of-peleg-chevion-as-president-and-chief-commercial-officer-301258544.html
SOURCE Invaio Sciences